

DirectConnect

Inside Yale Cancer Center

September 18, 2015

Announcements

Closer to Free a Wonderful Day

Thank you for an amazing day last weekend! Our 5th annual Closer to Free Ride was a fantastic day of celebration and camaraderie with colleagues, friends, patients, and survivors. The ride surpassed all expectations with over 1,250 riders and 500 volunteers and has raised over \$1.5 million to date. Fundraising continues through the end of September and I look forward to sharing the final total with you.

In a day of many inspiring moments, the presentation of the Mark Reitsma Courage Award to Stephen Ackley-Ortiz stands out. In January 2011, he was diagnosed with Stage IV metastatic squamous cell carcinoma in his throat and his neck. A month later, he learned that he also had stage II colon cancer. After searching for a solution throughout the northeast, he found a team at Smilow who told him they could battle both cancers simultaneously. His unique treatment plan was, in his words, "brutal," but it worked and he immediately wanted to give back. Only a few months after completing his treatment, he rode 25 miles in the inaugural Closer to Free Ride. The next year he rode 100. In 5 years he's raised more than \$75,000 for Closer to Free to celebrate the fact that he is now cancer free!



from the desk of

Peter G. Schulam, MD, PhD

Director, Yale Cancer Center
and Physician-in-Chief,
Smilow Cancer Hospital (Interim)

Yale CANCER
CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

**SMILOW CANCER HOSPITAL
AT YALE-NEW HAVEN**

Recent News

Read recent articles featuring
experts from Yale Cancer Center

[News Center >>](#)

LATEST ARTICLES:



Telepharmacy Shows Its Worth in
Cancer Setting

[Read More >>](#)

Marna Borgstrom presenting Stephen Ackley-Ortiz with the
Mark Reitsma Courage Award

Patient Satisfaction Ranks High

Cathy Lyons reported our recent inpatient patient satisfaction scores, as compared to 15 of our NCI comprehensive cancer center peer organizations, in yesterday's faculty meeting and we should be very proud of the extraordinary scores that Smilow Cancer Hospital has achieved. Smilow is tied with MD Anderson for 4th place for overall assessment of patient satisfaction, behind only City of Hope, Roswell Park, and Moffitt. Other rankings include: 2 for facility; 3 for admission; 2 for room; 7 for meals; 3 for nurses; tied for 7 for tests and treatments; 2 for visitor and family experience; 5 for experience with physicians; 5 for discharge process; 3 for dealing with personal issues, including emotional support.

Program Project Grant Renewed

The National Cancer Institute recently awarded a five-year, \$4.7 million program project grant to investigators at Yale School of Medicine to continue studies on the role of viruses in tumorigenic transformation of cells. Virus infection is thought to account for approximately 15% of all human cancers worldwide, and studies of tumor viruses have historically provided insight into basic cellular processes including carcinogenesis, cell cycle control, and signal transduction.

The grant, "Molecular Basis of Cancer Virus Replication, Transformation, and Innate Defense," is currently in its 41st year and is one of the largest and longest-running basic science grants at Yale. Led by principal investigator, Daniel DiMaio, MD, PhD, the grant coordinates studies to understand how viral genes allow cells to escape normal growth controls and induce cancer.

[Learn More >>](#)



Dr. Moran Appointed to New Position

Congratulations to Dr. Meena Moran, Professor of Therapeutic Radiology, on her new appointment as Director of the Yale Radiation Therapy Breast Program. Dr. Moran is an internationally recognized expert in the area of breast cancer, with over 110 publications that have helped to shape our current approaches to breast cancer treatment. Her landmark paper



Money raised for Smilow Cancer Hospital and Yale Cancer Center with Closer to Free Ride

[Read More >>](#)



Realizing the Promise of Clinical Trials in Cancer Care

[Read More >>](#)

Join Yale Cancer Center on Facebook

Like us on Facebook 

LATEST POSTS:

Through GBM Heroes, CURE Media Group is honoring those who have made a difference in the field of glioblastoma (GBM).

If you have had an outstanding experience with one of your care providers in the Smilow Cancer Hospital Brain Tumor Program, we encourage you to nominate your clinician to be a GBM Hero.

in 2014 provided critical new consensus guidelines on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer and was recognized last year by Yale Cancer Center with a Clinical Research prize. She has also recently assumed the role of Medical Director of the Radiation Oncology program at Lawrence & Memorial Hospital.

Nominations for Annual YCC Awards

Yale Cancer Center is pleased to announce our call for nominations for our annual awards in the areas of excellence in research and clinical care. Each award will be announced at the Yale Cancer Center Conclave on Monday, November 23, 2015. The nomination deadline for all awards is Friday, October 16, 2015. Please send your submissions to [Christen Ruff](#).

Yale Cancer Center Research Prizes

Three Research Prizes will be awarded in support of excellence in the areas of basic science, clinical research, and cancer prevention and control. One award will be chosen in each area for a paper that is considered to have had the greatest impact on the field this year. The applicant must be a current member of the Cancer Center. The science in the publication must be cancer-focused. Please submit a PDF of your best publication (publication date from October 2014 to Sept 2015). To be eligible you must be either the first or last author of the publication.

Yale Cancer Center Award for Clinical Excellence

This award will be given to the physician who best exemplifies excellence in clinical care including superb clinical skills, use of a patient- and family-centered approach to care, and inclusion of a multi-disciplinary care model. Nominee must be a current member of Yale Cancer Center. Please nominate yourself or a peer and send a brief nomination letter (one page maximum).

Yale Cancer Center Lifetime Achievement Award

Yale Cancer Center recognizes the achievements of one of our senior members through our annual Lifetime Achievement award. Please send nomination suggestions for the award to Christen Ruff.

Notables

Dr. Rogerio Lilenbaum has been appointed to the Board of the **National Comprehensive Cancer Network**.

Yale Cancer Center had a great presence at the **World Lung Congress** last week in Denver, CO, including the following



Nominate Your GBM Hero Today!

[Read More >>](#)

This Saturday, The Cusano Family Brain Tumor Fund will host its second annual "Playing for the Cure: Brainstormin" concert at the Ballroom at The Outer Space in Hamden, Connecticut at 6:30pm. All proceeds will benefit the Yale Brain Tumor Program, where Dr. Joseph Piepmeier treated Christopher Cusano for a benign brain tumor in 2008.

Last year, "Playing for the Cure: Brainstormin" raised over \$10,000 to assist researchers in the development of groundbreaking therapies for areas in the brain unreachable by surgery.



[Read More >>](#)

Last Friday, physicians from Smilow Cancer Hospital and our Care Centers and the greater Connecticut Region gathered on Yale's West Campus for Smilow Cancer Hospital's 5th Anniversary Symposium. Chaired by Roy S. Herbst, MD, PhD and Patricia M. LoRusso, DO, the symposium focused on new and emerging

presentations:

Protein Expression and Outcome in Small Cell Lung Cancer (SCLC) and Therapeutic Targeting with Tarextumab (Anti-Notch 2/3), **Anne Chiang**

Enhancing Physical Wellbeing in Lung Cancer: Nursing and Allied Professionals, Discussant: **Marianne Davies**

Outcome Management in Lung Cancer Patients: Identification and Management of Unique Immune Mediated Toxicities, **Marianne Davies**

Clinical Trials: Thymoma, Mesothelioma and Other Thoracic Malignancies, Oral Session Moderator: **Frank Detterbeck**

Grand Rounds: Treatment of Thymic Malignancies, Surgery: **Frank Detterbeck**

Search for Genetic/Molecular Predictors of Immune Checkpoint Therapy - Role of KRAS, LKB1, Other Genetic Markers as Predictors for Immunotherapy, **Scott Gettinger**

Brigatinib (AP26113) Efficacy and Safety in ALK+ NSCLC: Phase 1/2 Trial Results, **Scott Gettinger**

Immunotherapy Biomarkers: Biology, Pathology, and Molecular Testing, PD-L1 Discussant: **Scott Gettinger**

A Phase II Trial of Pembrolizumab for Untreated Brain Metastases from Non-Small Cell Lung Cancer, **Sarah Goldberg**

Lung Cancer Pathogenesis - Novel Biomarkers and Approaches to Targeting These Pathways, **Roy Herbst**

Harnessing the Full Potential of the Immune System: PD1/PDL1 Studies, **Roy Herbst**

The New Frontier in NSCLC - Beyond EGFR, VEGF and ALK: Expanding the Paradigm to Include Patients Without Actionable mutations, **Roy Herbst**

A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): SWOG S0819, **Roy Herbst**

Immune Biology, Microenvironment and Novel Targets: Biology, Pathology, and Molecular Testing, Discussant: **Roy Herbst**

Lung Cancer Pathogenesis - Novel Biomarkers and Approaches to Targeting These Pathways, **Roy Herbst**

cancer treatments, and groundbreaking clinical research.

Attendees gathered outside during their morning break to snap this group photo.




[Read More >>](#)


Follow Yale Cancer Center on Twitter


Follow us on 

LATEST TWEETS:

 Mediterranean Diet Linked to Reduced Breast Cancer Risk <http://nyti.ms/1ihtHtw> via [@nytimeswell](#)

 Child cancer charity gives Yale researcher grant <http://wp.me/p4ySuM-Icx> via [@WTNH](#)

 New Haven men: There is still time to come for a free prostate screenings today from 5-7:30 pm <http://wp.me/p4ySuM-Iff> via [@WTNH](#)

 Spoken like a true [#cancer](#) survivor, "It's important that we fund, fund, fund" cancer research [@AACRhttp://bit.ly/1MrFLFX](#)

 Dr. Peter Schulam on Yale's

Employee Profile: Shelley Jolie

With 22 years of experience as an oncology nurse, Shelley Jolie, RN, BSN, CORLN, CNML, was an ideal candidate when a new role opened for a Patient Service Manager for the Department of Radiation Oncology at Smilow. Four years later, the program has grown, and she now manages two other sites in addition to Smilow Cancer Hospital, at the Shoreline Medical Center and in Hamden.



Radiation Oncology runs the gamut for treatment in terms of cancer type and patient age. They treat all age groups from infants, to children, to adults to senior citizens, all with varying cancers. Nursing Disease Team Leaders focus on specific disease areas and attend tumor boards and conferences. Their knowledge and expertise is shared with other members of the nursing care team so that nurses can provide exceptional care to all patients regardless of disease or treatment center. Working alongside the nurses are the radiation therapists who together with physicians, physics and dosimetry, work to ensure that each treatment is delivered safely, accurately, and with compassion.

Shelley commented, "Being in a leadership role requires us to communicate effectively with other managers and our teams to ensure a cohesive vision for our department and our patients. And in the end, that is who it is all about, not us, but the patients."

Radiation Oncology can be very black and white, Shelley explained, and is a very technical and precision driven field. Her nursing team strives to add a human component that makes patients feel welcome and safe. The department consistently achieves some of the highest Press Ganey scores across all ambulatory sites at YNH. "I am so proud of my team. They do amazing work each day and I am blessed to be a part of this organization. With the opening of Smilow, care is more accessible to patients and I am constantly impressed with the quality of care Smilow delivers to our patients."

Frank Claudio, Director of Radiation Oncology, commented, "Shelley's commitment to her job and organization is only surpassed by her passion for our patients. Whether looking to improve clinical quality or ride 100 miles for Closer to Free, she always gives of herself and seeks to make a difference in the lives of those we are fortunate to care for."

assertive approach to watchful waiting for [#prostatecancer](#)
<http://bit.ly/1LyA0Ah>

Closer to Free

closer to free

The fund to advance cancer research and enhance patient care

Events

September 18; 1:00 PM

YCC Molecular Virology Research Program

SHM I-304

The Torsin Activator LULL1 is Important for Efficient Growth of HSV-1

Liz Turner

[Read More >>](#)

September 18; 1:00 PM

YCC Developmental Therapeutics & Signal Transduction Research Programs

SHM I-116

Combination Signaling Therapies for Melanoma and Carcinoma

David Stern, PhD

[Read More >>](#)

September 19; 7:00 AM

Yale CME Conference

TAC N-107

The Evolving Role of Imaging in the Diagnosis and Treatment of Prostate Cancer

Preston Sprenkle, MD

[Read More >>](#)

September 19; 6:30 PM

Funding and Award Opportunities

The Yale PITCH Program

PITCH, Program in Innovative Therapeutics for Connecticut's Health, was enabled by a \$10 Million investment from the Connecticut Bioscience Innovation Fund. This program will facilitate assay development, screening and medicinal chemistry fully supporting user fees and assay/chemistry reagent costs for Yale and UCONN projects with the potential to translate Connecticut's academic research into new ventures in the State. Projects will be reviewed and accepted to the Program by an External Advisory Board.

Application Deadline: October 1, 2015

[Learn More >>](#)

Elsa U. Pardee Foundation Grants

The Elsa U. Pardee Foundation funds research to investigators in United States non-profit institutions proposing research directed toward identifying new treatments or cures for cancer. The Foundation particularly encourages grant applications for a one year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified.

Application Deadline: October 1, 2015

[Learn More >>](#)

Assay Validation For High Quality Markers For NCI-Supported Clinical Trials

The purpose of this Funding Opportunity Announcement (FOA) is to improve the development and validation of molecular diagnostics for the treatment, control, or prevention of cancer. This FOA includes, but is not limited to, the validation of prognostic, predictive or response markers for treatment and markers for cancer control or prevention trials. Applicants should have an assay that works in human samples and whose importance is well justified for development into a clinical assay. In addition, analytical validation of assays for these markers should be achieved when the application is submitted so that clinical validation may be achieved with little further analytical validation needed. This supplement may be used to support acquisition of specimens from retrospective or prospective

Yale Brain Tumor Center Fundraiser

The Outer Space Ballroom
Playing for the Cure ...
'Brainstormin': A Give Back Music Festival

[Read More >>](#)

September 20; 6:00 PM

Yale Cancer Center Answers

WNPR
CNS Tumors and Gamma Knife
Veronica Chiang, MD

[Read More >>](#)

September 21; 1:30 PM

Yale New Haven Health / Employee and Family Resources

NP4-101A
Strategies to Prevent Compassion Fatigue and Take Care of Self

[Read More >>](#)

September 22; 12:00 PM

Yale Cancer Center Grand Rounds

Park Street Auditorium
Getting to the Heart of the Hematology/Oncology Patient with Advanced Cardiac Imaging
Lauren Baldassarre, MD
The Yale Fertility Preservation Program

Pasquale Patrizio, MD

[Read More >>](#)

September 23; 5:00 PM

Yale New Haven Health / Employee and Family Resources

NP4-101A
Mindfulness Solutions

[Read More >>](#)

September 24; 9:00 AM

Therapeutic Radiology Grand

studies from NCI-supported or other clinical trials. Clinical laboratory staff, technical and other needs must be an integral part of the application. Assays proposed for this FOA may be used to validate existing assays for use in other cancer clinical trials, observational studies or populations. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, clinicians, statisticians and clinical laboratory scientists and staff. This FOA is not intended to support trials that assess the clinical utility of a marker/assay but is intended to develop assays to the point where their clinical utility could be assessed in other trials.

Application Deadline: October 7, 2015

[Learn More >>](#)

Smoking Cessation within the Context of Lung Cancer Screening

The goal of this Funding Opportunity Announcement (FOA) is to improve the effectiveness and/or implementation of smoking cessation interventions delivered to current smokers who undergo low-dose computed tomography (LDCT) lung cancer screening. The proposed projects must be aimed at determining:

- a) the key components and characteristics of an effective smoking cessation intervention delivered in the LDCT setting; and/or
- b) characteristics of an implementation strategy to optimally incorporate existing evidence-based smoking cessation intervention(s) into the LDCT setting.

Application Deadline: October 8, 2015

[Learn More >>](#)

The National Cancer Institute (NCI) announces the reissuance of the Outstanding Investigator Award (R35)

The NCI is pleased to announce the reissuance of the Outstanding Investigator Award (OIA) funding opportunity announcement: [PAR-15-342](#). The OIA will support investigators with outstanding records of productivity in cancer research with \$600,000 in direct costs per year for 7 years to provide funding stability.

The OIA will allow funded investigators the freedom to embark on long-term projects of unusual potential in cancer research; the opportunity to take greater risks and be more adventurous in their lines of inquiry; and sufficient time to develop new techniques.

Rounds

NP4-101A

Genetic Counseling and Cancer Screening

Karinia Brierley, MS

[Read More >>](#)

September 25; 7:30 AM

Yale CME/Digestive Disease Event

Park Street Auditorium

19th Therapeutic ERCP/EUS Workshop

Harry Aslanian, MD and Priya Jamidar, MD

[Read More >>](#)

September 27; 9:00 AM

CT Women of Hope

Putnam Elks Club

3rd Annual Ann Miller 5K

[Read More >>](#)

September 27; 10:00 AM

YSM Discovery to Cure Program

Woolsey Hall

Beverly E. Levy Walk

[Read More >>](#)

September 27; 6:00 PM

Yale Cancer Center Answers

WNPR

Environmental Causes of Cancer

Yawei Zhang, PhD, MPH

[Read More >>](#)

September 28; 1:30 PM

Yale New Haven Health / Employee and Family Resources

NP4-101A

Strategies to Prevent Compassion Fatigue and Take Care of Self

[Read More >>](#)

Applications must be submitted by Institutions who have nominated a Program Director/Principal Investigator (PD/PI) with outstanding productivity in cancer research as a recipient of NCI grant(s) for at least the last 5 consecutive calendar years. The PD/PI will be expected to commit at least 50% of his/her research activities to the OIA; the Institution will be expected to commit at least 20% salary support. Interested applicants should read the reissuance closely, since there are a few significant changes from the first issuance, including eligibility requirements and research strategy page length.

Application Deadline: October 23, 2015

[Learn More >>](#)

National Comprehensive Cancer Network® (NCCN®) /ImmunoGen Inc. Grants

National Comprehensive Cancer Network® (NCCN®) is pleased to announce that it has received a research grant from ImmunoGen Inc. to support NCCN investigator initiated pre-clinical studies of mirvetuximab soravtansine (previously known as IMGN853) in the treatment of solid tumors of special interest.

Application Deadline: October 26, 2015

[Learn More >>](#)

Melanoma Research Alliance Grants

The Melanoma Research Alliance (MRA) is pleased to announce a Request for Proposals (RFP) for high-impact translational research that has the potential to lead to near-term clinical application in melanoma prevention, detection, diagnosis, staging, and treatment. This cycle, proposals will be accepted for Team Science Awards, Young Investigator Awards, Academic-Industry Partnership Awards (for Established Investigators), and Special Opportunity Awards. Team Science Letter of Intent Due: October 12, 2015 Young Investigator Award and Academic-Industry Partnership

Proposals Due: November 16, 2015

[Learn More >>](#)

Women's Health Research at Yale Pilot Project Awards

All proposals must demonstrate innovative approaches to understanding women's health or sex differences, and describe a clear path to implementation for clinical or public health benefit. These awards offer up to \$35,000 (direct costs only) in funding for research designed to meet a clear need in advancing women's health.

Application Deadline: October 29, 2015

September 28; 5:00 PM

Cancer Genetics and Prevention Program

Orchard Medical Building, Suite 107-109

Ribbon Cutting Ceremony

[Read More >>](#)

September 29; 12:00 PM

Yale Cancer Center Grand Rounds

Park Street Auditorium

Improving Communication about Goals of Care

Cardinale Smith, MD

[Read More >>](#)

September 29; 5:00 PM

YCC Breast Clinical Lecture Series

Smilow First Floor Conference Room, 1-330

[Read More >>](#)

September 29; 5:00 PM

Yale Cancer Center CME Evening Oncology Series

NP4-101A&B

New Agents for Cancer Treatment

Rogerio Lilenbaum, MD

[Read More >>](#)

September 30; 4:30 PM

YCC Cancer Prevention & Control Research Program

YSPH, Room 216

Diagnostic Delays in Patients with Symptomatic Cancer: Frequency, Risk Factors, Likely Mechanisms and Lessons from UK Research and Policy

Georgios Lyratzopoulos, MD

[Read More >>](#)

[Learn More >>](#)

Leslie H. Warner Postdoctoral Fellowships

Yale Cancer Center is pleased to announce the Leslie H. Warner Postdoctoral Fellowships to be awarded for one year commencing December 1, 2015, to fellows conducting cancer research with a Yale Cancer Center member. The Fellowships will support innovative basic, translational, clinical, or population-based cancer research. Candidates who began postdoctoral studies on or after December 1, 2014 are eligible for this award. Up to four applications will be funded.

Application Deadline: October 29, 2015

[Learn More >>](#)

Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Funding Opportunity

Briefly, this funding opportunity is aimed at advancing research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. The PLCO biorepository offers high quality, pre diagnostic, serial blood samples (serum/plasma/DNA/red cells/cryo-preserved whole blood) ideal for investigation of the causes and the natural history of various cancers and for pivotal validation of promising blood-based early detection biomarkers. The FOA supports biochemical and genetic analysis of cancer risk as well as discovery and validation of early detection biomarkers. The proposed research must involve the use of PLCO biospecimens.

Application Deadline: February 17, 2016

[Learn More >>](#)

Recent Publications

Human Papillomavirus-Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials.

Bhatia A, Burtness B.

J Clin Oncol. 2015 Sep 8.

[Read More >>](#)

Family involvement for breast cancer decision making among Chinese-American women.

September 30; 5:00 PM

Yale New Haven Health / Employee and Family Resources Presents

NP4-101A

Mindfulness Solutions

[Read More >>](#)

October 1; 12:30 PM

Pathology Grand Rounds

Fitkin Amphitheatre, LMP 1094

Genomic Pathology as a Driver of Improved Ovarian Cancer Control

David Huntsman, MD

[Read More >>](#)

Submissions

Please submit your recent publication and grant announcements to:

Renee Gaudette

Director, Public Affairs and Marketing

renee.gaudette@yale.edu

 Forward to a Friend

Lee SK, Knobf MT.

Psychooncology. 2015 Sep 16.

[Read More >>](#)

Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart.

Bar N, Parker TL, Dhodapkar MV.

J Clin Oncol. 2015 Sep 14.

[Read More >>](#)

Interfacing Inorganic Nanowire Arrays and Living Cells for Cellular Function Analysis.

Kwak M, Han L, Chen JJ, Fan R.

Small. 2015 Sep 9.

[Read More >>](#)

Prevalence, Diagnosis and Management of Pancreatic Cystic Neoplasms: Current Status and Future Directions.

Farrell JJ.

Gut Liver. 2015 Sep 23;9(5):571-89.

[Read More >>](#)

Deciphering the associations between gene expression and copy number alteration using a sparse double Laplacian shrinkage approach.

Shi X, Zhao Q, Huang J, Xie Y, Ma S.

Bioinformatics. 2015 Sep 3.

[Read More >>](#)

Afatinib plus cetuximab delays resistance compared to single agent erlotinib or afatinib in mouse models of TKI-naïve EGFR L858R-induced lung adenocarcinoma.

Pirazzoli V, Ayeni D, Meador CB, Sanganahalli B, Hyder F, de Stanchina E, Goldberg SB, Pao W, Politi K.

Clin Cancer Res. 2015 Sep 4.

[Read More >>](#)

Risk of Vascular Toxicity with Platinum-based Chemotherapy in Elderly Patients with Bladder Cancer.

Gupta A, Long JB, Chen J, Gross CP, Feldman DR, Steingart

RM.

J Urol. 2015 Sep 1.

[Read More >>](#)

Dual HER2\PIK3CA targeting overcomes single-agent acquired resistance in HER2 amplified uterine serous carcinoma cell lines in vitro and in vivo.

Lopez S, Cocco E, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Terranova C, Angioli R, Santin AD.

Mol Cancer Ther. 2015 Sep 2.

[Read More >>](#)

Factors Predictive of Improved Survival in Patients With Brain Metastases From Gynecologic Cancer: A Single Institution Retrospective Study of 47 Cases and Review of the Literature.

Gressel GM, Lundsberg LS, Altwerger G, Katchi T, Azodi M, Schwartz PE, Ratner ES.

Int J Gynecol Cancer. 2015 Sep 1.

[Read More >>](#)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.

Black JD, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Br J Cancer. 2015 Sep 1.

[Read More >>](#)